Share
Share
Portal hypertension is a complication of children with biliary atresia. It results from progression of liver scarring (fibrosis) and can lead to gastrointestinal bleeding and accumulation of fluid in the abdomen (also known as ascites). In this study, investigations from the Childhood Liver Disease Research Network analyzed the blood of patients to identify protein that increase in children with portal hypertension. Investigators analyzed over 1,000 proteins using an assay known as proteomics. Among the proteins that increased in babies with portal hypertension they found that semaphorin 6B (SEMA6B) alone and three other protein combinations (SEMA6B+SFRP3, SEMA6B+COMMD7, and VCAM1+BMX) had high accuracy to identify portal hypertension. Analyzing liver biopsies, the new protein biomarkers showed increased expression in liver vascular cells (endothelial cells), bile duct epithelium (cholangiocytes), and immune cells within portal triads.
Conclusion
Large-scale proteomics identified SEMA6B, SFRP3, COMMD7, BMX, and VCAM1 as biomarkers highly associated with clinical portal hypertension in children with biliary atresia. The expression of the biomarkers in liver epithelial, endothelial, and immune cells support their potential role in the mechanisms that cause portal hypertension.
January 8, 2025 — Christopher Spera, President and CEO of Arbor Research Collaborative for Health, announced the election of Bryan K. Johnson, JD, MBA to the Arbor Research board of directors in 2025. Mr. Johnson was a co-founder of Insight Policy Research in 2001. His strategic development, operational management, and financial oversight led the start-up
December 5, 2024 — Arbor Research Collaborative for Health is proud to announce an innovative collaboration with the Nephrology Associates of Northern Illinois and Indiana (NANI), the largest private nephrology practice in the United States. This partnership marks a significant milestone in advancing chronic kidney disease (CKD) research and management by leveraging NANI’s extensive patient-level
Arbor Research Collaborative for Health is excited to announce a partnership with CSL Vifor to launch a multinational registry designed to capture real-world outcomes of difelikefalin (Kapruvia®), a newly-approved treatment for chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis (HD) patients. Known as PARADIGM (PAn european Registry Addressing pruritus in DIalysis with a focus on Goal
The Health Resources and Services Administration (HRSA) has selected Arbor Research Collaborative for Health (Arbor Research) as one of 14 organizations who will lead the modernization of the Organ Procurement and Transplantation Network (OPTN). Arbor Research received one of the five initial efforts, focusing on improving patient safety and policy compliance systems and processes overseen